Flagship Harbor Advisors’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $518K | Sell |
9,878
-68
| -0.7% | -$3.6K | 0.02% | 510 |
|
|
2026
Q1 | $549K | Buy |
9,946
+78
| +0.8% | +$4.23K | 0.02% | 460 |
|
|
2025
Q4 | $484K | Sell |
9,868
-821
| -8% | -$38.3K | 0.02% | 449 |
|
|
2025
Q3 | $461K | Sell |
10,689
-566
| -5% | -$22.1K | 0.02% | 514 |
|
|
2025
Q2 | $432K | Buy |
11,255
+731
| +7% | +$27.9K | 0.02% | 510 |
|
|
2025
Q1 | $408K | Sell |
10,524
-87
| -0.8% | -$3.19K | 0.02% | 486 |
|
|
2024
Q4 | $359K | Sell |
10,611
-301
| -3% | -$10.8K | 0.02% | 523 |
|
|
2024
Q3 | $446K | Sell |
10,912
-495
| -4% | -$20.3K | 0.02% | 446 |
|
|
2024
Q2 | $439K | Sell |
11,407
-54
| -0.5% | -$2.27K | 0.03% | 425 |
|
|
2024
Q1 | $491K | Sell |
11,461
-461
| -4% | -$19K | 0.03% | 389 |
|
|
2023
Q4 | $442K | Buy |
11,922
+175
| +1% | +$6.28K | 0.03% | 390 |
|
|
2023
Q3 | $426K | Buy |
11,747
+19
| +0.2% | +$674 | 0.04% | 373 |
|
|
2023
Q2 | $418K | Sell |
11,728
-4,089
| -26% | -$147K | 0.03% | 385 |
|
|
2023
Q1 | $563K | Buy |
15,817
+1,470
| +10% | +$51.4K | 0.05% | 328 |
|
|
2022
Q4 | $504K | Sell |
14,347
-11,292
| -44% | -$376K | 0.05% | 333 |
|
|
2022
Q3 | $755K | Buy |
25,639
+12,010
| +88% | +$455K | 0.09% | 234 |
|
|
2022
Q2 | $742K | Sell |
13,629
-136
| -1% | -$7.51K | 0.08% | 250 |
|
|
2022
Q1 | $749K | Buy |
13,765
+288
| +2% | +$15.6K | 0.07% | 269 |
|
|
2021
Q4 | $743K | Buy |
13,477
+8,642
| +179% | +$450K | 0.07% | 281 |
|
|
2021
Q3 | $241K | Hold |
4,835
| – | – | 0.03% | 549 |
|
|
2021
Q2 | $241K | Buy |
+4,835
| New | +$232K | 0.03% | 550 |
|
|
2020
Q4 | – | Sell |
-3,546
| Closed | -$166K | – | 1007 |
|
|
2020
Q3 | $166K | Sell |
3,546
-5,352
| -60% | -$268K | 0.02% | 515 |
|
|
2020
Q2 | $453K | Buy |
8,898
+5,940
| +201% | +$305K | 0.07% | 272 |
|
|
2020
Q1 | $140K | Buy |
2,958
+955
| +48% | +$50.9K | 0.03% | 461 |
|
|
2019
Q4 | $118K | Sell |
2,003
-17
| -0.8% | -$946 | 0.02% | 570 |
|
|
2019
Q3 | $107K | Sell |
2,020
-722
| -26% | -$37.1K | 0.02% | 563 |
|
|
2019
Q2 | $137K | Buy |
2,742
+593
| +28% | +$29.8K | 0.03% | 489 |
|
|
2019
Q1 | $112K | Sell |
2,149
-169
| -7% | -$8.45K | 0.02% | 532 |
|
|
2018
Q4 | $110K | Sell |
2,318
-7,736
| -77% | -$381K | 0.03% | 486 |
|
|
2018
Q3 | $503K | Sell |
10,054
-95
| -0.9% | -$4.83K | 0.09% | 231 |
|
|
2018
Q2 | $511K | Buy |
+10,149
| New | +$511K | 0.1% | 212 |
|
Other funds holding GSK
JEST
Flagship Harbor Advisors's GSK Position: Q2 2026 in Review
Flagship Harbor Advisors reduced its GSK (GSK) stake by 0.68% in Q2 2026, selling an estimated $3.6K and leaving 9,878 shares worth $518K. The position accounts for 0.02% of the portfolio, ranked #510.
Flagship Harbor Advisors first reported a position in GSK in Q2 2018 and has held it in 31 quarters since. The position peaked at $755K in Q3 2022. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.
- Flagship Harbor Advisors held 9,878 shares of GSK worth $518K as of Q2 2026.
- Flagship Harbor Advisors sold 68 GSK shares in Q2 2026, an estimated $3.6K.
- GSK made up 0.02% of Flagship Harbor Advisors's portfolio in Q2 2026, its #510 holding.
- Flagship Harbor Advisors first reported a position in GSK in Q2 2018 and has held it in 31 quarters since.
- Flagship Harbor Advisors's GSK position peaked at $755K in Q3 2022.
- 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.
Based on Flagship Harbor Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.